狂犬病病毒模仿脂质体用于阿尔茨海默病的向基因治疗
Gulsah Erel-Akbaba1, Hasan Akbaba2, Ozan Karaman3
1Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, Izmir Katip Celebi University, 35620 Izmir, Turkey.
International journal of pharmaceutics
|November 26, 2024
概括
这项研究开发了一种与RVG29装饰的新型脂肪体基因载体,用于向大脑输送RNA干扰疗法. 该载体有效地传递siRNA使BACE1沉默,显示出治疗阿尔茨海默病等神经系统疾病的前景.
科学领域:
- 生物医学工程 生物医学工程
- 神经科学是一个神经科学.
- 基因治疗 基因治疗
背景情况:
- RNA干扰 (RNAi) 显示出神经系统疾病的潜力,但由于中枢神经系统障碍和核酸不稳定性而面临挑战.
- 有效地将基因传递到大脑仍然是开发RNAi疗法的重要障碍.
研究的目的:
- 设计和评估一种模仿病毒的非病毒基因载体,用于向大脑向的RNAi输送.
- 在阿尔茨海默氏病模型中利用狂犬病病毒糖蛋白 (RVG29) 装饰的脂质体 (f(Lipo) -RVG29) 来传递小干扰RNA (siRNA) 准BACE1.
主要方法:
- 用RVG29装饰的脂质体 (f(Lipo) -RVG29) 封装siRNA的制备.
- 脂质体载体特性 (大小,形状,泽塔潜力,核酶保护) 的表征.
- 在体外基因传递和沉默疗效评估,体外脑部成像和体内BACE1表达分析.
主要成果:
- f(Lipo) -RVG29 矢量显示出最佳的粒子大小 (<80 nm),球形,正泽塔潜力和siRNA保护.
- RVG29功能化显著增强了体外基因传递和沉默功效.
- 活体成像证实了脑组织中f ((Lipo) -RVG29沉积的增加.
- 在体内研究显示,大脑中mRNA和蛋白质水平上BACE1表达的实质性抑制.
结论:
- 开发的RVG29装饰的脂质体非病毒载体是针对大脑向RNAi治疗的有前途的系统.
- 结合RVG29连接体和生物启发性脂质体,为克服中枢神经系统中的基因传递挑战提供了一种协同方法.
- 这一策略有可能用于治疗神经退行性疾病,如阿尔茨海默病.
更多相关视频
08:27Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
Published on: July 29, 2018
11.8K
08:33Development of an Alpha-synuclein Based Rat Model for Parkinson's Disease via Stereotactic Injection of a Recombinant Adeno-associated Viral Vector
Published on: February 28, 2016
13.2K
相关概念视频
02:30siRNA - Small Interfering RNAs
16.6K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
16.6K
01:22Alzheimer's Disease: Treatment
165
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
165